Perosphere Pharma is a private company focused on developing rescue drugs.
Perosphere Pharma's lead investigational drug product candidate, ciraparantag (PER977), is an intravenously administered small synthetic water soluble new molecular entity intended for use as a reversal agent for the orally administered direct Factor Xa inhibitors and low molecular weight heparin. Ciraparantag is undergoing clinical testing to evaluate its ability to rapidly re-establish normal blood coagulation in subjects anticoagulated with Daiichi Sankyo Co., Ltd.'s SavaysaTM/Lixiana® (edoxaban), Johnson & Johnson's and Bayer HealthCare AG's Xarelto® (rivaroxaban) and Bristol-Myers Squibb Company's and Pfizer Inc.'s Eliquis® (apixaban). There is currently no FDA-approved reversal agent for these anticoagulants. Ciraparantag is currently undergoing Phase 2 clinical trials in the United States.